XDEMVY

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jul 24, 2023

   2 yr 11 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Jul 24, 2028

   in 2 yr 2 mo

4. Patent 8383659 expires

   Listed drug substance patent expiration.

   Jan 17, 2030

   in 3 yr 8 mo

5. Patent 10835517 expires

   Listed method-of-use patent (U-3674) expiration.

   Dec 14, 2038

   in 12 yr 8 mo

6. Patent 11197847 expires

   Listed method-of-use patent (U-3674) expiration.

   Dec 14, 2038

   in 12 yr 8 mo

7. Patent 11690826 expires

   Listed method-of-use patent (U-3674) expiration.

   Dec 14, 2038

   in 12 yr 8 mo

8. Patent 11690827 expires

   Listed method-of-use patent (U-3674) expiration.

   Dec 14, 2038

   in 12 yr 8 mo

9. Patent 11752137 expires

   Listed drug product patent expiration.

   Dec 14, 2038

   in 12 yr 8 mo

10. Patent 12171750 expires

    Listed method-of-use patent (U-3674) expiration.

    Dec 14, 2038

    in 12 yr 8 mo

11. Patent 12213964 expires

    Listed drug product patent expiration.

    Dec 14, 2038

    in 12 yr 8 mo

12. Patent 12364685 expires

    Listed drug product patent expiration.

    Dec 14, 2038

    in 12 yr 8 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Jul 24, 2028

  in 2 yr 2 mo

Listed patents (9)